Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Empagliflozin in Japanese Patients with Type 2 Diabetes
NCT01193218Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2010
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of empagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Boehringer Ingelheim. Started Sep 2010; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01193218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01193218.